Douglas Flora: Our June issue of AI in Precision Oncology
Douglas Flora shared a post by on LinkedIn:
“It’s here! Our June issue of AI in Precision Oncology is full of great content for the masters, the curious, and the confused. It’s time to join us-AI is not going away.
Start with my interview with American Cancer Society and American Cancer Society Cancer Action Network (ACS CAN) CEO, Karen Knudsen MBA for her take on this subject.
Move on then to some reviews by Vivek Subbiah and colleagues, and add some practical hints from Scott Penberthy and Sarah McGough to help you get started.
Please check this issue out, share/repost to your circles, subscribe individually or through your institution AND please let me know what you want to see in our August issue?
Please consider reposting or sharing to reach those in your circles who can help us on our mission to demystify these tools, working to build an AI-enabled healthcare world that improves the quality of care we deliver and the QOL of those delivering that important care.”.
Quoting
“Online Now! The New Issue of AI in Precision Oncology
We’re excited to announce that the third issue of AI in Precision Oncology is now live! This edition features groundbreaking research and insights into the integration of AI in precision medicine, offering new hope and strategies in our fight against cancer.
Read it here.
Submit Today
Explore the latest developments and join our journey to revolutionize oncology with AI. Together, we can achieve unprecedented progress in cancer research and treatment.
Thank you for your continued support and for being part of our community!”
Source: Douglas Flora/LinkedIn and
Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, overseeing clinical operations, strategic planning, and the expansion of cancer programs. He is also the co-founder of the Center for Precision Medicine; Genomic Health.
As the Editor-in-Chief of ‘AI in Precision Oncology,’ the first peer-reviewed academic journal dedicated to this field, he plays a pivotal role in advancing research. He is also an active board member of the American Cancer Society and ACCC, where he contributes to advocacy, education, and innovation within the cancer community.